292 related articles for article (PubMed ID: 27615271)
41. Validity of the International HIV Dementia Scale in South Africa.
Joska JA; Westgarth-Taylor J; Hoare J; Thomas KG; Paul R; Myer L; Stein DJ
AIDS Patient Care STDS; 2011 Feb; 25(2):95-101. PubMed ID: 21214343
[TBL] [Abstract][Full Text] [Related]
42. APRI and FIB-4 scores are not associated with neurocognitive impairment in HIV-infected persons.
Libertone R; Balestra P; Lorenzini P; Pinnetti C; Ricottini M; Menichetti S; Plazzi MM; Giannetti A; Tozzi V; Antinori A; Ammassari A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19658. PubMed ID: 25394162
[TBL] [Abstract][Full Text] [Related]
43. Correlations between computerized battery testing and a memory questionnaire for identification of neurocognitive impairment in HIV type 1-infected subjects on stable antiretroviral therapy.
Garvey LJ; Yerrakalva D; Winston A
AIDS Res Hum Retroviruses; 2009 Aug; 25(8):765-9. PubMed ID: 19678764
[TBL] [Abstract][Full Text] [Related]
44. Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection.
Pérez-Santiago J; Schrier RD; de Oliveira MF; Gianella S; Var SR; Day TR; Ramirez-Gaona M; Suben JD; Murrell B; Massanella M; Cherner M; Smith DM; Ellis RJ; Letendre SL; Mehta SR
J Neurovirol; 2016 Apr; 22(2):191-200. PubMed ID: 26428514
[TBL] [Abstract][Full Text] [Related]
45. Plasma Cytokine Levels As Predictors of Global and Domain-Specific Human Immunodeficiency Virus-Associated Neurocognitive Impairment in Treatment-Naive Individuals.
Ruhanya V; Jacobs GB; Paul R; Joska J; Seedat S; Nyandoro G; Engelbrecht S; Glashoff RH
J Interferon Cytokine Res; 2021 Apr; 41(4):153-160. PubMed ID: 33885338
[TBL] [Abstract][Full Text] [Related]
46. Peripheral Blood Mitochondrial DNA Copy Number Obtained From Genome-Wide Genotype Data Is Associated With Neurocognitive Impairment in Persons With Chronic HIV Infection.
Hulgan T; Kallianpur AR; Guo Y; Barnholtz-Sloan JS; Gittleman H; Brown TT; Ellis R; Letendre S; Heaton RK; Samuels DC;
J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e95-e102. PubMed ID: 30531306
[TBL] [Abstract][Full Text] [Related]
47. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort.
Robertson KR; Su Z; Margolis DM; Krambrink A; Havlir DV; Evans S; Skiest DJ;
Neurology; 2010 Apr; 74(16):1260-6. PubMed ID: 20237308
[TBL] [Abstract][Full Text] [Related]
48. Association of age and time of disease with HIV-associated neurocognitive disorders: a Japanese nationwide multicenter study.
Kinai E; Komatsu K; Sakamoto M; Taniguchi T; Nakao A; Igari H; Takada K; Watanabe A; Takahashi-Nakazato A; Takano M; Kikuchi Y; Oka S;
J Neurovirol; 2017 Dec; 23(6):864-874. PubMed ID: 28971376
[TBL] [Abstract][Full Text] [Related]
49. Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?
Muñoz-Moreno JA; Fumaz CR; Prats A; Ferrer MJ; Negredo E; Pérez-Alvarez N; Moltó J; Gómez G; Garolera M; Clotet B
J Neurovirol; 2010 May; 16(3):208-18. PubMed ID: 20450380
[TBL] [Abstract][Full Text] [Related]
50. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection.
Mehta SH; Thomas DL; Torbenson M; Brinkley S; Mirel L; Chaisson RE; Moore RD; Sulkowski MS
Hepatology; 2005 Jan; 41(1):123-31. PubMed ID: 15619237
[TBL] [Abstract][Full Text] [Related]
51. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
52. Pattern of neurocognitive function in patients receiving boosted protease inhibitor monotherapy: a detailed neuropsychological study.
González-Baeza A; Carvajal F; Bayón C; Pérez-Valero I; Estébanez M; Bernardino JI; Monge S; Lagarde M; Hernando A; Arnalich F; Arribas JR
J Neurovirol; 2014 Aug; 20(4):362-70. PubMed ID: 24760361
[TBL] [Abstract][Full Text] [Related]
53. [GeSIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2014)].
;
Enferm Infecc Microbiol Clin; 2014; 32(7):446.e1-42. PubMed ID: 24953253
[TBL] [Abstract][Full Text] [Related]
54. Circulating HIV DNA Correlates With Neurocognitive Impairment in Older HIV-infected Adults on Suppressive ART.
de Oliveira MF; Murrell B; Pérez-Santiago J; Vargas M; Ellis RJ; Letendre S; Grant I; Smith DM; Woods SP; Gianella S
Sci Rep; 2015 Nov; 5():17094. PubMed ID: 26603568
[TBL] [Abstract][Full Text] [Related]
55. Cognitive screening in treatment-naïve HIV-infected individuals in Hong Kong - a single center study.
Chan FCC; Chan P; Chan I; Chan A; Tang THC; Lam W; Fong WC; Lee MP; Li P; Chan GHF
BMC Infect Dis; 2019 Feb; 19(1):156. PubMed ID: 30760220
[TBL] [Abstract][Full Text] [Related]
56. Impact of HIV and Atiretroviral Therapy on Neurocognitive Outcomes Among School-Aged Children.
Brahmbhatt H; Boivin M; Ssempijja V; Kagaayi J; Kigozi G; Serwadda D; Violari A; Gray RH
J Acquir Immune Defic Syndr; 2017 May; 75(1):1-8. PubMed ID: 28169874
[TBL] [Abstract][Full Text] [Related]
57. Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders.
Borjabad A; Morgello S; Chao W; Kim SY; Brooks AI; Murray J; Potash MJ; Volsky DJ
PLoS Pathog; 2011 Sep; 7(9):e1002213. PubMed ID: 21909266
[TBL] [Abstract][Full Text] [Related]
58. Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder.
Gates TM; Cysique LA; Siefried KJ; Chaganti J; Moffat KJ; Brew BJ
AIDS; 2016 Feb; 30(4):591-600. PubMed ID: 26825032
[TBL] [Abstract][Full Text] [Related]
59. Adiponectin and interleukin-6, but not adipose tissue, are associated with worse neurocognitive function in HIV-infected men.
Lake JE; Vo QT; Jacobson LP; Sacktor N; Miller EN; Post WS; Becker JT; Palella FJ; Ragin A; Martin E; Munro CA; Brown TT
Antivir Ther; 2015; 20(2):235-44. PubMed ID: 25810377
[TBL] [Abstract][Full Text] [Related]
60. Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy.
Garvey L; Surendrakumar V; Winston A
HIV Clin Trials; 2011; 12(6):333-8. PubMed ID: 22189152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
